Chair and medical director of the Developmental Therapeutics Committee and co-chair of the Genitourinary Committee for U.S. Oncology Research
Nicholas j vogelzang m d 2014 inspired excellence award recipient las vegas heals
Nicholas J. Vogelzang is a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as Medical Director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.
What to do with the post abiraterone enzalutamide patient nicholas j vogelzang
Career
Vogelzang joined Comprehensive Cancer Centers of Nevada in 2009 as a medical oncologist and serves as Medical Director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. Since 2004, he has been Head of the Genitourinary Oncology and Clinical Professor of Medicine for the University of Nevada School of Medicine in Las Vegas and Reno, Nevada.
He served as Director, Executive Vice President for Academic Affairs and Professor at Nevada Cancer Institute (NVCI) from 2004 to 2009.
During his tenure at the University of Chicago, he served as Professor of Medicine and Surgery (Urology) (1993 to 2003), Director for the University of Chicago Cancer Research Center (1999–2003), and was named the first Fred C. Buffett Professor in Medicine and Chair in Genitourinary Oncology (1999–2003).
Vogelzang received his M.D. from the University of Illinois at Chicago in 1974. He completed his internship, residency and chief residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, followed by his fellowship in medical oncology at the University of Minnesota in Minneapolis. Vogelzang became the first editor of the Textbook of Genitourinary Oncology and remains the lead editor today.
Research
In 2002, Vogelzang directed the largest Phase II trial for mesothelioma using pemetrexed (brand name Alimta, by Eli Lilly). Pemetrexed is an antifolate, a class of drugs that targets the folic acid metabolic pathway. The results of the trial showed tumors shrank in 41 percent of patients on pemetrexed in combination with a more commonly used chemotherapy agent called cisplatin. Only 17 percent of patients receiving cisplatin alone experienced tumor shrinkage. Additionally, those on the pemetrexed combination lived nearly three months longer than those on cisplatin alone.
Active research support
Vogelzang is actively involved in many research studies to test new therapies and treatments including:
A double-blind, randomised, multiplied dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases. The study began in October 2010 and is supported by Algeta USA.
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy. The study began in March 2010 and is supported by Cougar Biotechnology.
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer. The study began in April 2009 and is supported by Cougar Biotechnology.
A Registry of Sipuleucel-T Therapy in men with advanced prostate Cancer. The study began in June 2010 and is supported by Dendreon.
A Phase 1/2., Open label, dose escalation, selected dose comparison trail of TOK-001 for the Treatment of Chemotherapy naïve castration resistant Prostate Cancer. The study began in September 2009 and is supported by Tokai.
Professional memberships
Vogelzang served on committees for the American Society of Clinical Oncology (ASCO), as well as its board of directors from 1993 to 1996, and is a former president of the Illinois Division of the American Cancer Society. Vogelzang was the principal investigator at the University of Chicago for Cancer and Leukemia Group B (CALGB) from 1988 to 1999, and chair of the CALGB Prostate Committee from 1993 to 1999.
Vogelzang is a corporate consultant for the following companies: Aveo Pharmaceuticals Inc., Celgene Corporation, Dendreon, Exelixis Inc., Novartis AG, OncoGeneX/Teva Pharmaceutical Industries Ltd., Veridex, and Viamet.
He is also a member of the speakers' bureaus for Caris Life Sciences, Dendreon, Eli Lilly and Company, Inc., Novartis AG, and Sanofi-Aventis U.S.
Published works
Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robinson LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ: Clinical cancer advances 2012: Annual report on progress against cancer from the American Society of Clinical Oncoloy J Clin Oncol 2013 January 1
Sonpavde G, Pond, GR, Fougeray R, Choueiri Tk, Au AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J: Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advance urothelial carcinoma Eur Urol. 2012 Nov 26
Smith DG, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn UN, Vogelzang NJ, Small AL, Harzstark, MS, Gordon UN, Vaishampayan NB, Hass AI, Alexander I, Spira PN, Primo Nl JR, Lin CC, Srivivas S, Sella A, Schoffski P, Scheffold C, Weitzman AL, Hussain M: Cabozantinib in patients with advanced prostate cancer:results of a phase II randomized discontinuation trial J Clin Oncol. 2012 Nov 19
Yuh BE, Ruel N, Wilson TG, Vogelzang N, Pal SK (May 2013). "Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.". J Urol. 189 (5): 1682–6. PMC 3926865 . PMID 23123547. doi:10.1016/j.juro.2012.10.120.
Dreicer R, Garcia JA, Rini B, Vogelzang N, Srinivas S, Somer B, Peipei S, Kania M, Raghavan D: A randomized, double-blind, placebo-controlled, phase 2 study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castrate-resistant metastatic prostate cancer submitted to Investigation New Drug (IND)
Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ: Treatment patterns in metastatic renal cell carcinoma: A retrospective chart review in US community oncology practices Submitted Journal of Oncology Practice (JOP)
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB JR, Sternberg CN, Li JH, Kheoh T, Haqq CM, De Bono JS; for the COU-AA-301 Investigatiors; Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer; final overall survival analysis of the COU-AA-301 radnomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct 13; Epub 2012 Sept 18
Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Huston TE,: Everolimus vs. Temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology network. Clin Genitourin Cancer. 2012 Oct 11
Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass B, Zhong ZD, Friberg G, Appleman LJ: A phase 1, open –label study of trebananib (AMG 386) combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma Trebanib (AMG 386)
Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, Demarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA; Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial Lancet Oncol. 2012 Jul 13. (epub ahead of print)
Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA, Quinn Dl, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato III SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE; Multicenter, Double-Blind Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma. 2012 June 4. (e-pub ahead of print)
Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM., J Clin Oncol. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. 2011 May 20;29(15):2040-5. doi:10.1200/JCO.2010.32.2776 PMID 21502546
Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J., "A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar;12(3):211-4.
Smith DC, Tangen CM, Hussain MHA, Van Veldhuizen, Jr PJ, Hartner GW, Stuart RK, Mills GM, Vogelzang NJ, Thompson IM. Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate. Southwest Oncology Group (SWOG) S0032 Urology 2011 Feb 18
Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff DD, Kawabe T, Sharma S: Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid tumors. Clinical Cancer Res. 2011 January 10. (e-pub ahead of print)
Galsky MD, Hahn NM, Rosenberg J, Sonpavde S, Hutson T, Oh W, Dreicer R, Vogelzang NJ, Sternberg C, Bajorin D, Bellmunt D. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. Journal of Clinical Oncology 2011 (IN PRESS)
Agarwal N, Vogelzang NJ., BJU Int., Secondary hormonal manipulations in the treatment of castration refractory prostate cancer. 2011 Jul;108(2):227-8. doi: 10.1111/j.1464-410X.2010.09970.x. Epub 2010 Nov 24.
In the media
Study May Alter Approach to Prostate Cancer The New York Times, June 1, 2014.
Top Docs 2014 - Dr. Nicholas Vogelzang Vegas Seven, May 29, 2014.
Is There A Link Between Prostate Cancer and Chronic Inflammation? Forbes, April 21, 2014.
The Doctor Will "Like" You Now Desert Companion, August 2013.
Antiangiogenic Agents, Chemotherapy, and the Treatment of Metastatic Transitional Cell Carcinoma Journal of Clinical Oncology, January 22, 2013.
A Man of Many Battles: Genitourinary Expert Spurs Advances Amid Challenges onclive.com, November 12, 2012.
Event seeks to raise awareness for prostate cancer Las Vegas Review-Journal, September 22, 2011.
Clinical trials give cancer patients hope, time Las Vegas Review-Journal, January 29, 2011.
Nicholas J. Vogelzang, MD, Receives Award From the Kidney Cancer Association. Medscape Today: Oncologists in the News, October 6, 2010.
With Dr. Nicholas Vogelzang KSNV Ch.3, July 26, 2010.
Patients from several states seek cancer treatmentLas Vegas Review-Journal July 20, 2010.
Cancer patients find new hope, FDA approves new but costly treatment for prostate cancer. Las Vegas Review-Journal July 16, 2010.
Study: Cancer Patients at Higher Suicide Risk. Time Magazine, February 3, 2010
Awards and honors
Vogelzang has been recognized for his work by many of the leading medical groups and research organizations in the United States. Some of his notable honors include:
Member of the Board of Advisors, Johns Hopkins Greenberg Bladder Cancer Institute - 2014
Named one of the "Top Doctors - Medical Oncology" in Vegas Seven - May 2014
Laureate Award and medallion of The ACP Nevada Chapter - 2013
